Abstract: Polyketides are one of the largest classes of natural products, possessing immense structural diversity and complex chemical architectures. Working in an assembly-line fashion, multi-modular polyketide synthases (PKSs) assemble and tailor readily available acyl-CoAs within the host cell into large, complex, chiral molecules. Each of these PKSs comprises a series of modules that can be further dissected into a series of domains responsible for the extension of the polyketide back-bone through condensation and selective reductive processing of an acyl-CoA building block. The collinear architecture of these modules, apparent by inspection of the domains present and the predictive selectivity motifs harbored within, provide insights into the chemical connectivity and stereochemical configuration of the polyketide metabolite from analysis of its coding sequence. While PKSs have been traditionally studied for production of pharmaceuticals, engineered modular PKSs have the potential to be an extraordinarily effective retrosynthesis platform for the bio-production of products from biofuels and commodity chemicals to both pharmaceutical and nonpharmaceutical fine and specialty chemicals. By rearranging existing polyketide modules and domains, one can exquisitely control chemical structure from DNA sequence alone. However, this potential has only just begun to be realized as the compounds that have been made using engineered PKSs represent a small fraction of the potentially accessible chemical space. In my talk, I will highlight work from our laboratory where we have engineered PKSs to produce a variety of commodity and specialty chemicals and materials monomers and developed software and high throughput robotic platforms to enable design and construction of PKSs in high throughput.

Speakers’ bio:

Jay Keasling is the Philomathia Distinguished Professor of Alternative Energy at the University of California, Berkeley in the Department of Bioengineering and the Department of Chemical and Biomolecular Engineering, senior faculty scientist at Lawrence Berkeley National Laboratory, and Chief Executive Officer of the Joint BioEnergy Institute (JBEI). Dr. Keasling’s research focuses on metabolic engineering of microorganisms for environmentally friendly synthesis of drugs, chemicals, and fuels. Keasling received a B.S. in Chemistry and Biology from the University of Nebraska and M.S. and Ph.D. in Chemical Engineering from the University of Michigan, and did post-doctoral research in biochemistry at Stanford University. He is a member of the National Academy of Engineering, the National Academy of Inventors, and the American Academy of Arts and Sciences. Keasling has published over 550 papers in peer-reviewed journals and has over 75 issued patents. Keasling has won numerous awards. Keasling is the founder of Amyris, LS9, Lygos, Napigen, Demetrix, Maple Bio, Apertor Pharma, Zero Acre Farms, Cyklos Materials, BioMia, and ResVita Bio.